The Experts below are selected from a list of 261 Experts worldwide ranked by ideXlab platform
Jack Rychik - One of the best experts on this subject based on the ideXlab platform.
-
Tricuspid Valve dysplasia with severe Tricuspid regurgitation fetal pulmonary artery size predicts lung viability in the presence of small lung volumes
Fetal Diagnosis and Therapy, 2010Co-Authors: Aruna Nathan, Bradley S Marino, Troy E Dominguez, Sarah Tabbutt, Susan C Nicolson, Denise Donaghue, Thomas L Spray, Jack RychikAbstract:Congenital Tricuspid Valve Disease (Ebstein’s anomaly, Tricuspid Valve dysplasia) with severe Tricuspid regurgitation and cardiomegaly is associated with poor prognosis. Fetal echocardiography can acc
-
Tricuspid Valve dysplasia with severe Tricuspid regurgitation fetal pulmonary artery size predicts lung viability in the presence of small lung volumes
Fetal Diagnosis and Therapy, 2010Co-Authors: Aruna T Nathan, Bradley S Marino, Troy E Dominguez, Sarah Tabbutt, Susan C Nicolson, Denise Donaghue, Thomas L Spray, Jack RychikAbstract:Congenital Tricuspid Valve Disease (Ebstein's anomaly, Tricuspid Valve dysplasia) with severe Tricuspid regurgitation and cardiomegaly is associated with poor prognosis. Fetal echocardiography can accurately measure right atrial enlargement, which is associated with a poor prognosis in the fetus with Tricuspid Valve Disease. Fetal lung volumetric assessments have been used in an attempt to predict viability of fetuses using ultrasonogram and prenatal MRI. We describe a fetus with Tricuspid dysplasia, severe Tricuspid regurgitation, right atrial enlargement and markedly reduced lung volumes. The early gestational onset of cardiomegaly with bilateral lung compression raised the possibility of severe lung hypoplasia with decreased broncho-alveolar development. Use of fetal echocardiography with measurement of pulmonary artery size combined with prenatal MRI scanning of lung volumes resulted in an improved understanding of this anomaly and directed the management strategy towards a successful Fontan circulation.
Josep Rodescabau - One of the best experts on this subject based on the ideXlab platform.
-
transcatheter interventions for Tricuspid Valve Disease what to do and who to do it on
Canadian Journal of Cardiology, 2021Co-Authors: Guillem Muntanecarol, Alberto Alperi, Laurent Faroux, Elisabeth Bedard, Francois Philippon, Francois Dagenais, Josep RodescabauAbstract:Abstract Tricuspid Valve Disease, and particularly the management of severe Tricuspid regurgitation (TR), has gained momentum in recent years. Although it is well known that this frequent condition is associated with poor clinical outcomes, these patients have been classically managed medically, leading to end-stage right ventricular heart failure. Moreover, late referral to surgery has contributed to a high rate of periprocedural complications and in-hospital surgical mortality. Thus, the development of a less invasive catheter-based therapy would be of high clinical relevance in this context. Several transcatheter Tricuspid Valve intervention (TTVI) devices have been developed in recent years. The particular characteristics of the Tricuspid Valve (large noncalcific annulus, presence of chief surrounding structures such as the conduction system or the right coronary artery) make multimodality imaging (eg, transesophageal echocardiography, computed tomography) key in the preprocedural assessment of TTVI. According to their mechanism of action and therapeutic target, TTVI includes transcatheter repair either with coaptation or annuloplasty systems, caval Valve devices, and transcatheter Tricuspid Valve replacement. The initial TTVI experience showed that most procedures were well tolerated, with high procedural success and low in-hospital and early mortality. Also, most TTVI recipients improved their functional status and recent data suggest improved outcomes compared with medical management. However, the rate of significant residual TR after transcatheter Tricuspid Valve repair remains high and very scarce data exist on longer term (beyond 6-12 months) outcomes. The present review provides an overview regarding the framework of chronic TR and TTVI therapeutic options, and describes the updated current evidence in this challenging field.
-
Tricuspid Valve Disease diagnosis prognosis and management of a rapidly evolving field
Nature Reviews Cardiology, 2019Co-Authors: Lluis Asmarats, Maurizio Taramasso, Josep RodescabauAbstract:Tricuspid Valve Disease, and particularly Tricuspid regurgitation, is a highly prevalent condition with a complex pathophysiology and long-term adverse consequences. Although historically neglected, Tricuspid Valve Disease has gained increasing recognition, with important advances in the assessment and management of this disorder over the past 2 decades. Surgical treatment remains the standard of care, but it continues to have one of the the highest death rates among all cardiac Valve-related procedures, and a broad range of patients still do not receive effective therapy for Tricuspid Valve Disease in contemporary clinical practice. Therefore, several alternative, less-invasive technologies for treating patients with severe, native Tricuspid Valve Disease at high surgical risk have been developed in the past decade, with promising early results. This Review summarizes key findings and highlights the latest developments in the diagnosis and management framework that are transforming clinical practice in the complex field of Tricuspid Valve Disease.
-
transcatheter Tricuspid Valve implantation of navigate bioprosthesis in a preclinical model
JACC: Basic to Translational Science, 2018Co-Authors: Jose L Navia, Josep Rodescabau, Samir R Kapadia, Haytham Elgharably, Gabriel Maluenda, Krzysztof Bartuś, Cristian Baeza, R Nair, Cesare Beghi, R C QuijanoAbstract:Highlights •Surgery for isolated Tricuspid regurgitation carries a high mortality risk, especially in the setting of right ventricular dysfunction and reoperation. •Transcatheter Valve therapy is as promising alternative for treatment of isolated Tricuspid Valve Disease associated with right heart failure. •The NaviGate bioprosthesis is a novel self-expanding Valved stent designed to treat functional Tricuspid regurgitation. •The preclinical evaluation shows that transcatheter Tricuspid Valve implantation using the NaviGate device is safe, is feasible through 2 different approaches, and results in a secure and stable engagement of the native annulus, with excellent hemodynamic and Valve performance.
-
diagnosis and treatment of Tricuspid Valve Disease current and future perspectives
The Lancet, 2016Co-Authors: Josep Rodescabau, Maurizio Taramasso, Patrick T OgaraAbstract:Summary The assessment and management of Tricuspid Valve Disease have evolved substantially during the past several years. Whereas Tricuspid stenosis is uncommon, Tricuspid regurgitation is frequently encountered and is most often secondary in nature and caused by annular dilatation and leaflet tethering from adverse right ventricular remodelling in response to any of several Disease processes. Non-invasive assessment of Tricuspid regurgitation must define its cause and severity; advanced three-dimensional echocardiography, MRI, and CT are gaining in clinical application. The indications for Tricuspid Valve surgery to treat Tricuspid regurgitation are related to the cause of the disorder, the context in which it is encountered, its severity, and its effects on right ventricular function. Most operations for Tricuspid regurgitation are done at the time of left-sided heart Valve surgery. The threshold for restrictive ring annuloplasty repair of secondary Tricuspid regurgitation at the time of left-sided Valve surgery has decreased over time with recognition of the risk of progressive Tricuspid regurgitation and right heart failure in patients with moderate or lesser degrees of Tricuspid regurgitation and Tricuspid annular dilatation, as well as with appreciation of the high risks of reoperative surgery for severe Tricuspid regurgitation late after left-sided Valve surgery. However, many patients with unoperated severe Tricuspid regurgitation are also deemed at very high or prohibitive surgical risk. Novel transcatheter therapies have begun to emerge for the treatment of Tricuspid regurgitation in such patients. Experience with such therapies is preliminary and further studies are needed to determine their role in the management of this disorder.
Thomas L Spray - One of the best experts on this subject based on the ideXlab platform.
-
Tricuspid Valve dysplasia with severe Tricuspid regurgitation fetal pulmonary artery size predicts lung viability in the presence of small lung volumes
Fetal Diagnosis and Therapy, 2010Co-Authors: Aruna Nathan, Bradley S Marino, Troy E Dominguez, Sarah Tabbutt, Susan C Nicolson, Denise Donaghue, Thomas L Spray, Jack RychikAbstract:Congenital Tricuspid Valve Disease (Ebstein’s anomaly, Tricuspid Valve dysplasia) with severe Tricuspid regurgitation and cardiomegaly is associated with poor prognosis. Fetal echocardiography can acc
-
Tricuspid Valve dysplasia with severe Tricuspid regurgitation fetal pulmonary artery size predicts lung viability in the presence of small lung volumes
Fetal Diagnosis and Therapy, 2010Co-Authors: Aruna T Nathan, Bradley S Marino, Troy E Dominguez, Sarah Tabbutt, Susan C Nicolson, Denise Donaghue, Thomas L Spray, Jack RychikAbstract:Congenital Tricuspid Valve Disease (Ebstein's anomaly, Tricuspid Valve dysplasia) with severe Tricuspid regurgitation and cardiomegaly is associated with poor prognosis. Fetal echocardiography can accurately measure right atrial enlargement, which is associated with a poor prognosis in the fetus with Tricuspid Valve Disease. Fetal lung volumetric assessments have been used in an attempt to predict viability of fetuses using ultrasonogram and prenatal MRI. We describe a fetus with Tricuspid dysplasia, severe Tricuspid regurgitation, right atrial enlargement and markedly reduced lung volumes. The early gestational onset of cardiomegaly with bilateral lung compression raised the possibility of severe lung hypoplasia with decreased broncho-alveolar development. Use of fetal echocardiography with measurement of pulmonary artery size combined with prenatal MRI scanning of lung volumes resulted in an improved understanding of this anomaly and directed the management strategy towards a successful Fontan circulation.
Susan C Nicolson - One of the best experts on this subject based on the ideXlab platform.
-
Tricuspid Valve dysplasia with severe Tricuspid regurgitation fetal pulmonary artery size predicts lung viability in the presence of small lung volumes
Fetal Diagnosis and Therapy, 2010Co-Authors: Aruna Nathan, Bradley S Marino, Troy E Dominguez, Sarah Tabbutt, Susan C Nicolson, Denise Donaghue, Thomas L Spray, Jack RychikAbstract:Congenital Tricuspid Valve Disease (Ebstein’s anomaly, Tricuspid Valve dysplasia) with severe Tricuspid regurgitation and cardiomegaly is associated with poor prognosis. Fetal echocardiography can acc
-
Tricuspid Valve dysplasia with severe Tricuspid regurgitation fetal pulmonary artery size predicts lung viability in the presence of small lung volumes
Fetal Diagnosis and Therapy, 2010Co-Authors: Aruna T Nathan, Bradley S Marino, Troy E Dominguez, Sarah Tabbutt, Susan C Nicolson, Denise Donaghue, Thomas L Spray, Jack RychikAbstract:Congenital Tricuspid Valve Disease (Ebstein's anomaly, Tricuspid Valve dysplasia) with severe Tricuspid regurgitation and cardiomegaly is associated with poor prognosis. Fetal echocardiography can accurately measure right atrial enlargement, which is associated with a poor prognosis in the fetus with Tricuspid Valve Disease. Fetal lung volumetric assessments have been used in an attempt to predict viability of fetuses using ultrasonogram and prenatal MRI. We describe a fetus with Tricuspid dysplasia, severe Tricuspid regurgitation, right atrial enlargement and markedly reduced lung volumes. The early gestational onset of cardiomegaly with bilateral lung compression raised the possibility of severe lung hypoplasia with decreased broncho-alveolar development. Use of fetal echocardiography with measurement of pulmonary artery size combined with prenatal MRI scanning of lung volumes resulted in an improved understanding of this anomaly and directed the management strategy towards a successful Fontan circulation.
Sarah Tabbutt - One of the best experts on this subject based on the ideXlab platform.
-
Tricuspid Valve dysplasia with severe Tricuspid regurgitation fetal pulmonary artery size predicts lung viability in the presence of small lung volumes
Fetal Diagnosis and Therapy, 2010Co-Authors: Aruna Nathan, Bradley S Marino, Troy E Dominguez, Sarah Tabbutt, Susan C Nicolson, Denise Donaghue, Thomas L Spray, Jack RychikAbstract:Congenital Tricuspid Valve Disease (Ebstein’s anomaly, Tricuspid Valve dysplasia) with severe Tricuspid regurgitation and cardiomegaly is associated with poor prognosis. Fetal echocardiography can acc
-
Tricuspid Valve dysplasia with severe Tricuspid regurgitation fetal pulmonary artery size predicts lung viability in the presence of small lung volumes
Fetal Diagnosis and Therapy, 2010Co-Authors: Aruna T Nathan, Bradley S Marino, Troy E Dominguez, Sarah Tabbutt, Susan C Nicolson, Denise Donaghue, Thomas L Spray, Jack RychikAbstract:Congenital Tricuspid Valve Disease (Ebstein's anomaly, Tricuspid Valve dysplasia) with severe Tricuspid regurgitation and cardiomegaly is associated with poor prognosis. Fetal echocardiography can accurately measure right atrial enlargement, which is associated with a poor prognosis in the fetus with Tricuspid Valve Disease. Fetal lung volumetric assessments have been used in an attempt to predict viability of fetuses using ultrasonogram and prenatal MRI. We describe a fetus with Tricuspid dysplasia, severe Tricuspid regurgitation, right atrial enlargement and markedly reduced lung volumes. The early gestational onset of cardiomegaly with bilateral lung compression raised the possibility of severe lung hypoplasia with decreased broncho-alveolar development. Use of fetal echocardiography with measurement of pulmonary artery size combined with prenatal MRI scanning of lung volumes resulted in an improved understanding of this anomaly and directed the management strategy towards a successful Fontan circulation.
